Abionyx Pharma SA
F:609
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Abionyx Pharma SA (609) under the Base Case is 1.169 EUR per share.
Compared with the current market price of 1.618 EUR, the stock appears
Overvalued by 28% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Abionyx Pharma Does
Abionyx Pharma SA is a biotechnology company that develops drug candidates based on a modified form of apolipoprotein A-I, a protein linked to how the body handles inflammation and lipid transport. Its work centers on therapies for serious diseases where the immune system, infection, or organ damage plays a major role, with a lead focus on rare and severe conditions. The company’s value is in turning early-stage scientific research into medicines that can move through clinical development and, if approved, become prescription treatments.
- Headquarters
- France FR
- Employees
- 49
- IPO date
- Mar 30, 2015
Earnings Waterfall
Abionyx Pharma SA
What is the Intrinsic Value of one Abionyx Pharma SA stock?
The intrinsic value for Abionyx Pharma SA (609) under the Base Case is 1.169 EUR.
Is Abionyx Pharma SA stock undervalued or overvalued?
Compared with the current market price of 1.618 EUR, the stock appears Overvalued by 28% .
